Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT

Research output: Contribution to journal › Article › peer-review

Standard

Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years : An RCT. / Williams, Fiona L R; Ogston, Simon; Hume, Robert; Watson, Jennifer; Stanbury, Kayleigh; Willatts, Peter; Boelen, Anita; Juszczak, Edmund; Brocklehurst, Peter; I2S2 team.

In: Pediatrics, Vol. 139, No. 5, e20163703, 05.2017.

Research output: Contribution to journal › Article › peer-review

Harvard

Williams, FLR, Ogston, S, Hume, R, Watson, J, Stanbury, K, Willatts, P, Boelen, A, Juszczak, E, Brocklehurst, P & I2S2 team 2017, 'Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT', Pediatrics, vol. 139, no. 5, e20163703. https://doi.org/10.1542/peds.2016-3703

APA

Williams, F. L. R., Ogston, S., Hume, R., Watson, J., Stanbury, K., Willatts, P., Boelen, A., Juszczak, E., Brocklehurst, P., & I2S2 team (2017). Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT. Pediatrics, 139(5), [e20163703]. https://doi.org/10.1542/peds.2016-3703

Vancouver

Williams FLR, Ogston S, Hume R, Watson J, Stanbury K, Willatts P et al. Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT. Pediatrics. 2017 May;139(5). e20163703. https://doi.org/10.1542/peds.2016-3703

Author

Williams, Fiona L R ; Ogston, Simon ; Hume, Robert ; Watson, Jennifer ; Stanbury, Kayleigh ; Willatts, Peter ; Boelen, Anita ; Juszczak, Edmund ; Brocklehurst, Peter ; I2S2 team. / Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years : An RCT. In: Pediatrics. 2017 ; Vol. 139, No. 5.

Bibtex

@article{bc911d90089347cdacab2ffc4f3ce753,
title = "Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT",
abstract = "BACKGROUND: The recommendation for enteral iodide intake for preterm infants is 30 to 40 μg/kg per day and 1 μg/kg per day for parenteral intake. Preterm infants are vulnerable to iodide insufficiency and thyroid dysfunction. The hypothesis tested whether, compared with placebo, iodide supplementation of preterm infants improves neurodevelopment.METHODS: A randomized controlled trial of iodide supplementation versus placebo in infants <31 weeks' gestation. Trial solutions (sodium iodide or sodium chloride; dose 30 μg/kg per day) were given within 42 hours of birth to the equivalent of 34 weeks' gestation. The only exclusion criterion was maternal iodide exposure during pregnancy or delivery. Whole blood levels of thyroxine, thyrotropin, and thyroid-binding globulin were measured on 4 specific postnatal days. The primary outcome was neurodevelopmental status at 2 years of age, measured by using the Bayley Scales of Infant Development-III. The primary analyses are by intention-to-treat, and data are presented also for survivors.RESULTS: One thousand two hundred seventy-three infants (637 intervention, 636 placebo) were recruited from 21 UK neonatal units. One hundred thirty-one infants died, and neurodevelopmental assessments were undertaken in 498 iodide and 499 placebo-supplemented infants. There were no significant differences between the intervention and placebo groups in the primary outcome: mean difference cognitive score, -0.34, 95% confidence interval (CI) -2.57 to 1.89; motor composite score, 0.21, 95% CI -2.23 to 2.65; and language composite score, -0.05, 95% CI -2.48 to 2.39. There was evidence of weak interaction between iodide supplementation and hypothyroxinemic status in the language composite score and 1 subtest score.CONCLUSIONS: Overall iodide supplementation provided no benefit to neurodevelopment measured at 2 years of age.",
keywords = "Brain, Child Development, Child, Preschool, Follow-Up Studies, Humans, Infant, Infant, Premature, Iodides, Parenteral Nutrition, Thyrotropin, Thyroxine, Thyroxine-Binding Globulin, Treatment Outcome, Journal Article, Pragmatic Clinical Trial",
author = "Williams, {Fiona L R} and Simon Ogston and Robert Hume and Jennifer Watson and Kayleigh Stanbury and Peter Willatts and Anita Boelen and Edmund Juszczak and Peter Brocklehurst and {I2S2 team}",
note = "Copyright {\textcopyright} 2017 by the American Academy of Pediatrics.",
year = "2017",
month = may,
doi = "10.1542/peds.2016-3703",
language = "English",
volume = "139",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

RIS

TY - JOUR

T1 - Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years

T2 - An RCT

AU - Williams, Fiona L R

AU - Ogston, Simon

AU - Hume, Robert

AU - Watson, Jennifer

AU - Stanbury, Kayleigh

AU - Willatts, Peter

AU - Boelen, Anita

AU - Juszczak, Edmund

AU - Brocklehurst, Peter

AU - I2S2 team

N1 - Copyright © 2017 by the American Academy of Pediatrics.

PY - 2017/5

Y1 - 2017/5

N2 - BACKGROUND: The recommendation for enteral iodide intake for preterm infants is 30 to 40 μg/kg per day and 1 μg/kg per day for parenteral intake. Preterm infants are vulnerable to iodide insufficiency and thyroid dysfunction. The hypothesis tested whether, compared with placebo, iodide supplementation of preterm infants improves neurodevelopment.METHODS: A randomized controlled trial of iodide supplementation versus placebo in infants <31 weeks' gestation. Trial solutions (sodium iodide or sodium chloride; dose 30 μg/kg per day) were given within 42 hours of birth to the equivalent of 34 weeks' gestation. The only exclusion criterion was maternal iodide exposure during pregnancy or delivery. Whole blood levels of thyroxine, thyrotropin, and thyroid-binding globulin were measured on 4 specific postnatal days. The primary outcome was neurodevelopmental status at 2 years of age, measured by using the Bayley Scales of Infant Development-III. The primary analyses are by intention-to-treat, and data are presented also for survivors.RESULTS: One thousand two hundred seventy-three infants (637 intervention, 636 placebo) were recruited from 21 UK neonatal units. One hundred thirty-one infants died, and neurodevelopmental assessments were undertaken in 498 iodide and 499 placebo-supplemented infants. There were no significant differences between the intervention and placebo groups in the primary outcome: mean difference cognitive score, -0.34, 95% confidence interval (CI) -2.57 to 1.89; motor composite score, 0.21, 95% CI -2.23 to 2.65; and language composite score, -0.05, 95% CI -2.48 to 2.39. There was evidence of weak interaction between iodide supplementation and hypothyroxinemic status in the language composite score and 1 subtest score.CONCLUSIONS: Overall iodide supplementation provided no benefit to neurodevelopment measured at 2 years of age.

AB - BACKGROUND: The recommendation for enteral iodide intake for preterm infants is 30 to 40 μg/kg per day and 1 μg/kg per day for parenteral intake. Preterm infants are vulnerable to iodide insufficiency and thyroid dysfunction. The hypothesis tested whether, compared with placebo, iodide supplementation of preterm infants improves neurodevelopment.METHODS: A randomized controlled trial of iodide supplementation versus placebo in infants <31 weeks' gestation. Trial solutions (sodium iodide or sodium chloride; dose 30 μg/kg per day) were given within 42 hours of birth to the equivalent of 34 weeks' gestation. The only exclusion criterion was maternal iodide exposure during pregnancy or delivery. Whole blood levels of thyroxine, thyrotropin, and thyroid-binding globulin were measured on 4 specific postnatal days. The primary outcome was neurodevelopmental status at 2 years of age, measured by using the Bayley Scales of Infant Development-III. The primary analyses are by intention-to-treat, and data are presented also for survivors.RESULTS: One thousand two hundred seventy-three infants (637 intervention, 636 placebo) were recruited from 21 UK neonatal units. One hundred thirty-one infants died, and neurodevelopmental assessments were undertaken in 498 iodide and 499 placebo-supplemented infants. There were no significant differences between the intervention and placebo groups in the primary outcome: mean difference cognitive score, -0.34, 95% confidence interval (CI) -2.57 to 1.89; motor composite score, 0.21, 95% CI -2.23 to 2.65; and language composite score, -0.05, 95% CI -2.48 to 2.39. There was evidence of weak interaction between iodide supplementation and hypothyroxinemic status in the language composite score and 1 subtest score.CONCLUSIONS: Overall iodide supplementation provided no benefit to neurodevelopment measured at 2 years of age.

KW - Brain

KW - Child Development

KW - Child, Preschool

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Infant, Premature

KW - Iodides

KW - Parenteral Nutrition

KW - Thyrotropin

KW - Thyroxine

KW - Thyroxine-Binding Globulin

KW - Treatment Outcome

KW - Journal Article

KW - Pragmatic Clinical Trial

U2 - 10.1542/peds.2016-3703

DO - 10.1542/peds.2016-3703

M3 - Article

C2 - 28557747

VL - 139

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

M1 - e20163703

ER -